ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Nanobiotix SA

Nanobiotix SA (NBTX)

3.46
0.09
(2.67%)
At close: 30 January 8:00AM
3.46
0.00
( 0.00% )
After Hours: 9:16AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

NBTX News

Official News Only

NBTX Discussion

View Posts
glenn1919 glenn1919 2 months ago
NBTX.......................https://stockcharts.com/h-sc/ui?s=NBTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
NBTX...........................https://stockcharts.com/h-sc/ui?s=NBTX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 months ago
NBTX 10Q due 4/3
👍️0
Monksdream Monksdream 10 months ago
NBTX under $10
👍️0
Monksdream Monksdream 2 years ago
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0
Monksdream Monksdream 2 years ago
July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0

Your Recent History

Delayed Upgrade Clock